Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 15

recruiting
3 968
countries
28
conditions
2 103

329 trials match your criteria

Deafness

Not yet recruiting

Study on Gene Therapy AAVAnc80-hOTOF for Patients with Sensorineural Hearing Loss from Otoferlin Gene Mutations

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Aavanc80-3'Hotof

Neuroblastoma

Not yet recruiting

Study of ABTL0812 with Irinotecan and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium 2-Hydroxylinoleate

Bacterial infection

Not yet recruiting

Study on Cefiderocol for Treating Gram-negative Bacterial Infections in Hospitalized Infants Under 3 Months

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Cefiderocol

Study on the Safety and Tolerability of Sisunatovir in Infants and Children with RSV Infection

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Sisunatovir

Krabbe's disease

Not yet recruiting

Study on Gene Therapy with AAVrh10 for Infants with Krabbe Disease Undergoing Stem Cell Transplantation

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Adeno-Associated Virus Serotype Rh10 Containing The Human Galc Gene

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:SpainSpain
  • Participants:0–17 years

Dermatitis atopic

Not recruiting

Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Ruxolitinib

Study on the Effects of TAK-881 and Hyaluronidase in Adults with Primary Immunodeficiency Diseases

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Dermatitis atopic

Not recruiting

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Baricitinib

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Effectiveness of Abrocitinib for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abrocitinib

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.